Elesclomol-induced increase of mitochondrial reactive oxygen species impairs glioblastoma stem-like cell survival and tumor growth
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Elesclomol-induced increase of mitochondrial reactive oxygen species impairs glioblastoma stem-like cell survival and tumor growth
Authors
Keywords
-
Journal
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
Volume 40, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-07-12
DOI
10.1186/s13046-021-02031-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Deregulated expression of the imprinted DLK1-DIO3 region in Glioblastoma Stem-like Cells: tumor suppressor role of lncRNA MEG3
- (2020) Mariachiara Buccarelli et al. NEURO-ONCOLOGY
- Elesclomol alleviates Menkes pathology and mortality by escorting Cu to cuproenzymes in mice
- (2020) Liam M. Guthrie et al. SCIENCE
- Single-cell RNA-seq reveals that glioblastoma recapitulates a normal neurodevelopmental hierarchy
- (2020) Charles P. Couturier et al. Nature Communications
- Repurposing elesclomol, an investigational drug for the treatment of copper metabolism disorders
- (2020) Vishal M. Gohil EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Next-generation characterization of the Cancer Cell Line Encyclopedia
- (2019) Mahmoud Ghandi et al. NATURE
- Mitochondrial metabolism promotes adaptation to proteotoxic stress
- (2019) Peter Tsvetkov et al. Nature Chemical Biology
- g:Profiler: a web server for functional enrichment analysis and conversions of gene lists (2019 update)
- (2019) Uku Raudvere et al. NUCLEIC ACIDS RESEARCH
- WebGestalt 2019: gene set analysis toolkit with revamped UIs and APIs
- (2019) Yuxing Liao et al. NUCLEIC ACIDS RESEARCH
- The Anticancer Agent Elesclomol Has Direct Effects on Mitochondrial Bioenergetic Function in Isolated Mammalian Mitochondria
- (2019) Modica-Napolitano et al. Biomolecules
- Glioblastoma endothelium drives bevacizumab‐induced infiltrative growth via modulation of PLXDC1
- (2018) Maria Laura Falchetti et al. INTERNATIONAL JOURNAL OF CANCER
- The clinical value of patient-derived glioblastoma tumorspheres in predicting treatment response
- (2017) Quintino Giorgio D’Alessandris et al. NEURO-ONCOLOGY
- KEGG: new perspectives on genomes, pathways, diseases and drugs
- (2016) Minoru Kanehisa et al. NUCLEIC ACIDS RESEARCH
- Redox Modulating NRF2: A Potential Mediator of Cancer Stem Cell Resistance
- (2016) In-geun Ryoo et al. Oxidative Medicine and Cellular Longevity
- UCN-01 enhances cytotoxicity of irinotecan in colorectal cancer stem-like cells by impairing DNA damage response
- (2016) Michele Signore et al. Oncotarget
- Cellular mechanisms of the cytotoxicity of the anticancer drug elesclomol and its complex with Cu(II)
- (2015) Brian B. Hasinoff et al. BIOCHEMICAL PHARMACOLOGY
- Cancer stem cells in glioblastoma
- (2015) Justin D. Lathia et al. GENES & DEVELOPMENT
- Detoxification of oxidative stress in glioma stem cells: Mechanism, clinical relevance, and therapeutic development
- (2014) Sung-Hak Kim et al. JOURNAL OF NEUROSCIENCE RESEARCH
- A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
- (2014) Mark R. Gilbert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
- (2014) Olivier L. Chinot et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bevacizumab for Newly Diagnosed Glioblastoma
- (2014) NEW ENGLAND JOURNAL OF MEDICINE
- Concise Review: Evidence for CD34 as a Common Marker for Diverse Progenitors
- (2014) Laura E. Sidney et al. STEM CELLS
- Syntheses and antitumor activities of N′1,N′3-dialkyl-N′1,N′3-di-(alkylcarbonothioyl) malonohydrazide: The discovery of elesclomol
- (2013) Shoujun Chen et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Acquired Resistance to Anti-VEGF Therapy in Glioblastoma Is Associated with a Mesenchymal Transition
- (2013) Y. Piao et al. CLINICAL CANCER RESEARCH
- Final Results of Phase III SYMMETRY Study: Randomized, Double-Blind Trial of Elesclomol Plus Paclitaxel Versus Paclitaxel Alone As Treatment for Chemotherapy-Naive Patients With Advanced Melanoma
- (2013) Steven J. O'Day et al. JOURNAL OF CLINICAL ONCOLOGY
- Reactive Oxygen Species in Cancer Stem Cells
- (2012) Xiaoke Shi et al. ANTIOXIDANTS & REDOX SIGNALING
- A BMP7 variant inhibits the tumorigenic potential of glioblastoma stem-like cells
- (2012) C M Tate et al. CELL DEATH AND DIFFERENTIATION
- The oncology drug elesclomol selectively transports copper to the mitochondria to induce oxidative stress in cancer cells
- (2012) Masazumi Nagai et al. FREE RADICAL BIOLOGY AND MEDICINE
- Glioblastoma: From Molecular Pathology to Targeted Treatment
- (2011) Timothy F. Cloughesy et al. Annual Review of Pathology-Mechanisms of Disease
- Angiogenesis and invasion in glioma
- (2011) Manabu Onishi et al. Brain Tumor Pathology
- Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice
- (2011) J. F. de Groot et al. NEURO-ONCOLOGY
- Transdifferentiation of glioblastoma cells into vascular endothelial cells
- (2011) Y. Soda et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells
- (2010) Lucia Ricci-Vitiani et al. NATURE
- Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
- (2009) Marta Pàez-Ribes et al. CANCER CELL
- Phase II, Randomized, Controlled, Double-Blinded Trial of Weekly Elesclomol Plus Paclitaxel Versus Paclitaxel Alone for Stage IV Metastatic Melanoma
- (2009) Steven O'Day et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
- (2009) Henry S. Friedman et al. JOURNAL OF CLINICAL ONCOLOGY
- Antiangiogenic therapies for high-grade glioma
- (2009) Andrew D. Norden et al. Nature Reviews Neurology
- FDA Drug Approval Summary: Bevacizumab (Avastin(R)) as Treatment of Recurrent Glioblastoma Multiforme
- (2009) M. H. Cohen et al. ONCOLOGIST
- Hypoxia-regulated protein expression, patient characteristics, and preoperative imaging as predictors of survival in adults with glioblastoma multiforme
- (2008) Jeannette R. Flynn et al. CANCER
- Mesenchymal differentiation of glioblastoma stem cells
- (2008) L Ricci-Vitiani et al. CELL DEATH AND DIFFERENTIATION
- Cancer Stem Cell Analysis and Clinical Outcome in Patients with Glioblastoma Multiforme
- (2008) R. Pallini et al. CLINICAL CANCER RESEARCH
- Elesclomol induces cancer cell apoptosis through oxidative stress
- (2008) J. R. Kirshner et al. MOLECULAR CANCER THERAPEUTICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search